Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation

References

• Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, et al. 2017. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3(4):524–548. doi:10.1001/jamaoncol.2016.5688.
   PubMed Web of Science ®Google Scholar
• Boloker G, Wang C, Zhang J. Updated statistics of lung and bronchus cancer in United States (2018). J Thorac Dis. 2018;10:1158–1161. doi:10.21037/jtd.2018.03.15.
   PubMed Web of Science ®Google Scholar
• Kuiper JL, Smit EF. Challenges in the management of EGFR-mutated non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors. Oncology. 2014;87:83–94. doi:10.1159/000362819.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Larriba JL, Lazaro-Quintela M, Cobo M, Domine M, Majem M, Garcia-Campelo R. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Transl Lung Cancer Res. 2017;6:S21–S34. doi:10.21037/tlcr.2017.10.03.
   PubMed Web of Science ®Google Scholar
• Chang YS, Choi CM, Lee JC. Mechanisms of epidermal growth factor receptor tyrosine kinase inhibitor resistance and strategies to overcome resistance in lung adenocarcinoma. Tuberc Respir Dis (Seoul). 2016;79:248–256. doi:10.4046/trd.2016.79.4.248.
   PubMedGoogle Scholar
• Koo HJ, Kim MY, Park S, Lee HN, Kim HJ, Lee JC, Kim S-W, Lee DH, Choi C-M. Non-small cell lung cancer with resistance to EGFR-TKI therapy: CT characteristics of T790M mutation-positive cancer. Radiology. 2018;289:227–237. doi:10.1148/radiol.2018180070.
   PubMed Web of Science ®Google Scholar
• Goag EK, Lee JM, Chung KS, Kim SY, Leem AY, Song JH, Jung JY, Park MS, Chang YS, Kim YS, et al. Usefulness of bronchoscopic rebiopsy of non-small cell lung cancer with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. J Cancer. 2018;9(6):1113–1120. doi:10.7150/jca.21650.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Kawaguchi T, Isa S, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, et al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res. 2015;21(15):3552–3560. doi:10.1158/1078-0432.CCR-14-2151.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun L, Xiong ZC, Sun X, Zhang SL, Ma JT, Han CB. Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs. Onco Targets Ther. 2017;10:2267–2279. doi:10.2147/OTT.S133082.
   PubMed Web of Science ®Google Scholar
• Kawamura T, Kenmotsu H, Omori S, Nakashima K, Wakuda K, Ono A, Naito T, Murakami H, Omae K, Mori K, et al. Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer. Clin Lung Cancer. 2018;19(2):e247–e52. doi:10.1016/j.cllc.2017.07.002.
   PubMed Web of Science ®Google Scholar
• Huang YH, Hsu KH, Tseng JS, Chen KC, Hsu CH, Su KY, Chen JJW, Chen H-W, Yu S-L, Yang T-Y, et al. The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Cancer Res Treat. 2018;50:1294–1303. doi:10.4143/crt.2017.512.
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Lantuejoul S, de Langen AJ, Thunnissen E. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: number 2 in the Series “pathology for the clinician” edited by Peter Dorfmuller and Alberto Cavazza. Eur Respir Rev. 2017;26(144):170007. doi:10.1183/16000617.0007-2017.
   PubMed Web of Science ®Google Scholar
• Grigoriu B, Berghmans T, Meert AP. Management of EGFR mutated nonsmall cell lung carcinoma patients. Eur Respir J. 2015;45:1132–1141. doi:10.1183/09031936.00156614.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, Seto T, Crino L, Ahn M-J, De Pas T, Besse B, Solomon BJ, Blackhall F, et al. Crizotinib versus Chemotherapy in advanced ALK -positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886.
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Buttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469(5):489–503. doi:10.1007/s00428-016-2000-3.
   PubMed Web of Science ®Google Scholar
• Zhang R, Chen B, Tong X, Wang Y, Wang C, Jin J, Tian P, Li W. Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA. Cancer Manag Res. 2018;10:1209–1218. doi:10.2147/CMAR.S161382.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Suda K, Kimura H, Matsumoto K, Arao T, Nagai T, Saijo N, Yatabe Y, Mitsudomi T, Nishio K, et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol. 2012;7(11):1640–1644. doi:10.1097/JTO.0b013e3182653d7f.
   PubMed Web of Science ®Google Scholar
• Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, et al. Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Curr Oncol. 2017;24(2):111–119. doi:10.3747/co.24.3524.
   PubMed Web of Science ®Google Scholar
• Liang H, Pan Z, Wang W, Guo C, Chen D, Zhang J, Zhang Y, Tang S, He J, Liang W, et al. The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis. J Thorac Dis. 2018;10(4):2311–2320. doi:10.21037/jtd.2018.03.150.
   PubMed Web of Science ®Google Scholar
• Kim EY, Kim A, Lee G, Lee H, Chang YS. Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma. BMC Cancer. 2018;18:1221. doi:10.1186/s12885-018-5116-9.
   PubMed Web of Science ®Google Scholar
• Kogure Y, Shigematsu F, Oki M, Saka H. T790M correlates with longer progression-free survival in non-small cell lung carcinomas harboring EGFR mutations. In Vivo. 2018;32:1199–1204. doi:10.21873/invivo.11364.
   PubMed Web of Science ®Google Scholar
• Contal C, O’Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data An. 1999;30:253–270. doi:10.1016/S0167-9473(98)00096-6.
   Web of Science ®Google Scholar